Zimmerman SS , Khatri A , Garnier-Amblard EC , Mullasseril P , Kurtkaya NL , Gyoneva S , Hansen KB , Traynelis SF , Liotta DC .

ES012870 NIEHS NIH HHS , MH094525 NIMH NIH HHS, NS065371 NINDS NIH HHS , NS078873 NINDS NIH HHS , T32 GM008602 NIGMS NIH HHS , R01 NS065371 NINDS NIH HHS , F32 NS078873 NINDS NIH HHS , T32 ES012870 NIEHS NIH HHS , R21 MH094525 NIMH NIH HHS

	Figure 1. Structure of screening hit. Chemical structure of methyl 4-(1-(2-(1H-indol-3-yl)ethyl)-3-acetyl-4-hydroxy-5-oxo-2,5-dihydro-1H-pyrrol-2-yl)benzoate (compound 1) that was identified as a positive modulator using a fluorescence-based screen of compound libraries in a cell line expressing diheteromeric GluN1/GluN2C NMDA receptors.
	Scheme 1. Synthesis of 1H-Pyrrol-2(5H)-onesReaction conditions: PPTS, rt, 1–24 h, 2% to >99% (procedure I). Final compounds 161–180, in which either the A or B ring is replaced, were also prepared using these conditions.
	Scheme 2. Route for the Synthesis of Pyruvate DerivativesReaction conditions: (a) diethyl oxalate, NaOEt, EtOH, 0 °C to rt, 4 h, 15% to >99% (procedure II); (b) TIPSCl, imidazole, rt, 6 h, >99%; (c) diethyl oxalate, NaOEt, EtOH, 0 °C to rt, 4 h, 28% (procedure II); (d) TBAF, 0 °C to rt, 1 h, 43%.
	Scheme 3. Synthetic Routes to Access Substituted Benzaldehydes 32–41Reaction conditions: (a) 2.0 equiv NBS, (PhCOO)2, reflux, 4 h, then AgNO3, rt, 3 h, 38–63%; (b) dibutyl vinylboronate, 5 mol % (PPh3)2PdCl2, NaCO3, reflux, 2 h, 68–80%; (c) O3; then (CH3)2S, −78 °C to rt, 12 h, 60–87%; (d) i-PrMgCl, DMF, −15 °C to rt, 3 h, 70%; (e) CO(g), (PPh3)2PdCl2, NaCO3, 110 °C, 8–24% (procedure IV); (f) CH3I, K2CO3, rt, 3 h, 58%.
	Scheme 4. Routes for the Synthesis of Amides 42–44 and Esters 45–47Reaction conditions: (a) Vilsmeier reagent, aq NH3, 0 °C, 16 h, 30%; (b) R2aR2bN where R2a = H and R2b = Me or where R2a = R2b = Me, DMAP, EDCI, 0 °C to rt, 24 h, 14–51%; (c) R2I where R2 = Et or R2 = i-Pr, K2CO3, rt, 4 h, 24–87%; (d) (CH3)2NCH(Ot-Bu)2, reflux, 11/2 h, 81%.
	Scheme 5. Route to Modifications at R11Reaction conditions: (a) TMSCH2N2, rt, 5 h, 46%; (b) NH4HCO2, reflux, 3 h, 14%; (c) Ac2O, pyridine, rt, 61/2 h, 7%; (d) R11C(O)Cl where R11 = CH2CH2CH3 or R11 = CH=CH2, TEA, −30 °C, 2 h, 20–35%.
	Figure 2. Compound 1 selectively potentiates the GluN1/GluN2C response. (A) Current traces for 1 at the GluN1/GluN2A, GluN1/GluN2B, GluN1/GluN2C, and the GluN1/GluN2D receptors. (B) Compound 1 selectively potentiates the GluN1/GluN2C receptor to a fitted maximum of 275 ± 10% with an EC50 of 24 ± 2.4, n = 12. (C) The EC50 for glycine in the absence and presence of 1 is 0.20 ± 0.01 μM (n = 6) and 0.16 ± 0.02 μM (n = 4), respectively. The EC50 for glutamate in the absence and presence of 1 is 0.8 ± 0.07 μM (n = 8) and 1.2 ± 0.04 μM (n = 6), respectively. The presence of 1 did not shift the glycine or glutamate EC50 values significantly. (D) The reversal potential is −5.1 ± 0.8 mV when activated by coagonists (100 μM glutamate and 30 μM glycine) and is −5.0 ± 1.2 mV (n = 6) when the GluN1/GluN2C receptor is potentiated by 1. The reversal potential was not significantly shifted in the presence of 1, suggesting that potentiation is independent of membrane potential.
	Figure 3. Composite concentration–effect curves for 106 enantiomers. Concentration–effect curves for the enantiomers of 106 demonstrate that only one enantiomer, 106a, is active, potentiating the GluN1/GluN2C receptor to a fitted maximum of 259 ± 8% of control with an EC50 of 18 ± 0.6 μM (n = 6).

Acker, Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. 2011, Pubmed

Acker, Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. 2011, Pubmed
Acker, Structure-activity relationships and pharmacophore model of a noncompetitive pyrazoline containing class of GluN2C/GluN2D selective antagonists. 2013, Pubmed
Akazawa, Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats. 1994, Pubmed
Bettini, Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors. 2010, Pubmed
Choi, The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. 1990, Pubmed
Costa, A novel family of negative and positive allosteric modulators of NMDA receptors. 2010, Pubmed , Xenbase
Coyle, Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. 2012, Pubmed
Duty, Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease. 2012, Pubmed
Furukawa, Subunit arrangement and function in NMDA receptors. 2005, Pubmed
Furukawa, Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core. 2003, Pubmed
Gauuan, Superoxide dismutase mimetics: synthesis and structure-activity relationship study of MnTBAP analogues. 2002, Pubmed
Hallett, Rationale for and use of NMDA receptor antagonists in Parkinson's disease. 2004, Pubmed
Hallett, Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. 2005, Pubmed
Hallett, Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. 2006, Pubmed
Hansen, Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists. 2010, Pubmed , Xenbase
Hansen, Pharmacological characterization of ligands at recombinant NMDA receptor subtypes by electrophysiological recordings and intracellular calcium measurements. 2008, Pubmed , Xenbase
Hansen, Subunit-selective allosteric inhibition of glycine binding to NMDA receptors. 2012, Pubmed
Hansen, Structural determinants of agonist efficacy at the glutamate binding site of N-methyl-D-aspartate receptors. 2013, Pubmed , Xenbase
Hu, Glutamate receptors in preclinical research on Alzheimer's disease: update on recent advances. 2012, Pubmed
Mathew, Ketamine for treatment-resistant unipolar depression: current evidence. 2012, Pubmed
Monyer, Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. 1994, Pubmed
Mosley, Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-methyl-D-aspartate receptor antagonists. 2010, Pubmed , Xenbase
Mullasseril, A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors. 2010, Pubmed
Nakanishi, Molecular diversity of glutamate receptors and implications for brain function. 1992, Pubmed
Nicoll, Expression mechanisms underlying NMDA receptor-dependent long-term potentiation. 1999, Pubmed
Paoletti, NMDA receptor subunits: function and pharmacology. 2007, Pubmed
Santangelo Freel, Synthesis and structure activity relationship of tetrahydroisoquinoline-based potentiators of GluN2C and GluN2D containing N-methyl-D-aspartate receptors. 2013, Pubmed , Xenbase
Traynelis, Glutamate receptor ion channels: structure, regulation, and function. 2010, Pubmed
Vicini, Functional and pharmacological differences between recombinant N-methyl-D-aspartate receptors. 1998, Pubmed
Yuan, Control of NMDA receptor function by the NR2 subunit amino-terminal domain. 2009, Pubmed , Xenbase
Zimmerman, Correction to "Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators". 2015, Pubmed